Q4 2023 Earnings Summary
- Pulmonx's ongoing CONVERT II pivotal trial for AeriSeal could expand the addressable market by approximately 20%. This study targets patients who are currently ineligible for Zephyr Valves due to the presence of collateral ventilation, potentially allowing Pulmonx to treat an additional 1 in 5 patients who undergo a Chartis assessment.
- The company's continued focus on improving account productivity and increasing local awareness in the U.S. is expected to drive growth in 2024. By sharing best practices with less mature accounts and investing in local education efforts, Pulmonx aims to enhance engagement and efficiency at existing Zephyr Valve centers, which could result in higher revenue.
- Entry into the Japanese market represents a significant future growth opportunity for Pulmonx. With a post-market approval study underway involving approximately 140 patients at 10 to 15 sites, the company anticipates broader commercialization in Japan after study completion, tapping into an estimated market of 100,000 patients who could benefit from the Zephyr Valve treatment.
- Pulmonx expects increased operating expenses in 2024 due to higher R&D expenses from enrolling in the CONVERT II trial and increased SG&A spending on commercial efforts, which may pressure profitability.
- The company's growth relies on optimizing existing accounts and increasing local awareness, but they have limited experience in increasing local awareness, raising execution risks in achieving growth targets.
- International growth, particularly in Japan, is expected to be minimal in 2024, with material revenue from Japan not anticipated until 2026, potentially limiting near-term revenue growth opportunities.
-
Gross Margins
Q: How can margins improve with higher volumes?
A: Management explained that as volume increases, especially in the U.S. market, gross margins will improve by spreading overhead costs across more units. Growing faster in the U.S. positively impacts global gross margins. However, increasing costs of raw materials may offset some gains. -
OpEx Increases
Q: Is increased local awareness driving higher OpEx?
A: Yes, the rise in operating expenses is partly due to increased spending on educating the community about the benefits of the Zephyr Valve. R&D expenses are also expected to increase in 2024 as the company invests in the CONVERT II study. -
International Growth and Japan Timing
Q: What's the outlook for international growth, especially in Japan?
A: The company is focusing on implementing best practices in major European markets in 2024, with significant revenue impact expected in 2025. In Japan, they plan to enroll about a third of patients into the study in 2024, with no material revenue expected until 2026 when they can fully operate commercially. -
New CEO's Agenda
Q: What is the new CEO's focus for growth?
A: Steve Williamson, the incoming CEO, is expected to continue executing existing plans and find additional ways to accelerate growth, leveraging his background in moving markets. The company remains in the early stages of market penetration with significant opportunities ahead. -
AeriSeal Time Lines and Opportunity
Q: What's the timeline and potential for AeriSeal?
A: The AeriSeal trial is commencing, with enrollment through next year to reach a couple hundred patients. Including follow-up and regulatory approval, impact is expected outside the normal scope of 2024–2026. AeriSeal could expand the total addressable market by about 20%, targeting patients who initially were not candidates for valves due to collateral ventilation. -
Potential Portfolio Additions
Q: Is there any possibility of adding related products?
A: While open to considering accretive additions that leverage their current focus, the company is cautious not to distract their finely tuned commercial organization. They will be extremely discriminating in evaluating opportunities.